A nano-bio-chip assay could someday be used to analyze a patient's saliva on board an ambulance, at the dentist’s office or at a neighborhood drugstore, helping save lives and prevent damage from cardiac disease, said a team led by researchers at University of Texas at Austin (UT Austin) at a recent American Association for Dental Research meeting. The device is the size of a credit card and can reportedly produce results in as little as 15 minutes. “Many heart attack victims, especially women, experience nonspecific symptoms and secure medical help too late, after permanent damage to the cardiac tissue has occurred,” said John T. McDevitt, principal investigator and designer of the nano-bio-chip. “Our tests promise to dramatically improve the accuracy and speed of cardiac diagnosis.” The test can reveal that a patient is currently having a heart attack necessitating quick treatment. It can also tell a patient that they are at high risk of having a future heart attack. It works like this: A patient spits into a tube and the saliva is then transferred to a credit card-sized lab card that holds the nano-bio-chip. The loaded card is inserted like an ATM card into an analyzer that manipulates the sample and analyzes the patient’s cardiac status on the spot. McDevitt, a professor of chemistry and biochemistry at the University of Texas at Austin, collaborated with scientists and clinicians at the University of Kentucky, University of Louisville and the University of Texas Health Science Center at San Antonio. He said the team took advantage of the recent identification of a number of blood serum proteins that are significant contributors to, and thus indicators of, cardiac disease. Leveraging microelectronics components and microfabrication developed initially for the electronic industry, they developed a series of compact nano-bio-chip sensor devices that are biochemically programmed to detect sets of these proteins in saliva, UT Austin said in a statement. Researchers from the University of Kentucky College of Dentistry tested saliva from 56 people who had a heart attack and 59 healthy subjects for 32 proteins associated with atherosclerosis, thrombosis and acute coronary syndrome. They found these proteins were in higher concentrations in saliva of heart attack victims -- and that specific salivary proteins were as accurate in the diagnosis of heart attack as those found in blood serum using current testing methods. “These are truly exciting findings, since use of these tests could lead to more rapid diagnosis and faster entry of patients into treatment scenarios that can save lives,” said Craig S. Miller, of the Kentucky team. McDevitt added, “What’s novel here is our ability to measure all such proteins in one setting and to use a noninvasive saliva sample, where low protein levels make such tests difficult, even with large and expensive lab instruments." Cardiovascular disease is the leading cause of death in developed countries, including the US, UT at Austin said. In 2008, an estimated 770,000 Americans will have a new coronary attack, and about 430,000 will have a recurrent attack. The new technology is in the clinical testing phase, but it is a strong candidate for further commercial development through the Austin, Texas company LabNow Inc., a startup venture that licensed the lab-on-a-chip technologies from UT Austin. LabNow’s first lab-on-a-chip product, now in development, targets HIV immune function testing and can be used in resource-strained settings like Africa. Lead investigators from The University of Texas at Austin are McDevitt, Nicolaos Christodoulides and Pierre N. Floriano; University of Texas Health Science Center at San Antonio lead researchers include Chih-Ko Yeh and Spencer Redding; at the University of Kentucky, Craig Miller, Michael J. Novak and Jeff Ebersole; University of Louisville, Denis Kinane. The research is supported by the National Institute of Dental and Craniofacial Research at the National Institutes of Health. For more information, visit: utexas.edu